Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.
about
Kallikreins as biomarkers for prostate cancerEmerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignanciesUrinary kallikrein 10 predicts the incurability of gastric cancerPlatelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.Exercise training can prevent cardiac hypertrophy induced by sympathetic hyperactivity with modulation of kallikrein-kinin pathway and angiogenesis.A novel autoantibody test for the detection of pre-neoplastic lung lesionsDown-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesionsA Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen aloneQuantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.Clinical significance of human kallikrein 12 gene expression in gastric cancer.The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers.Targeting kallikrein-related peptidases in prostate cancer.Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents.Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer.Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.Kallikrein–Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.Serum human kallikrein 7 represents a new marker for cervical cancer.Kallikrein-related peptidase 7 is a potential target for the treatment of pancreatic cancer.A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering
P2860
Q26862434-385E61E2-A7F5-4B81-9B6F-A05639E88014Q27007065-EC1ECCAB-74E0-4DDF-9F3E-C70B05EFB696Q33710081-D1F6FDF3-1228-416D-8263-C1BC4FD58426Q34056033-EB4542E1-CA7C-4EEC-8260-C785DF79D29CQ35116618-714138FF-D2D7-4ABB-AEE5-31ACFD17DF23Q35141435-412336BC-88C1-4826-AC8A-1567CF903F88Q35196992-5612A19D-0ED8-4BD3-934F-04416D52ECF4Q35785685-97349C83-14B6-42AB-A0D6-2B776CCC415CQ35964874-47EE1F92-B5DF-448C-8DDE-734DCEAEE3B7Q36447329-5506781F-DC5F-4AD9-A050-9280FFD4A97EQ36450504-803CD7F3-72C3-451E-9E99-38530285F7A1Q38106741-4CEAD01C-A114-4910-85C1-DFC94B14C9E0Q38191293-63A92BE3-CAEF-4C9B-B1AA-7B74E97FECBCQ38737293-E27FD976-9F5F-4681-BBA3-5183910D6CABQ38760061-0C0C2227-18EF-4C61-BB95-0529AB0DCFD5Q39552861-35C119F7-3205-487F-95B5-8B85EDEC3020Q39558472-20D67EF8-DE4B-4546-83B0-C3B548C01181Q39761179-7469DC6D-8B42-428F-B80E-FB483C08BDB2Q42139867-AE4E1BBF-1EE8-4F9E-919E-FB04AC9BD748Q43489162-DB665C5F-F324-466A-BA2C-5050B98C5119Q43704979-41289922-A5B2-4D44-896E-6CCFF32FBB51Q44315577-A79BFB84-0164-424E-9EDF-419E9C836DD8Q45720150-A774EEC0-7010-4C93-86B3-41E90B884742Q49852055-7D13FB79-EB79-402C-A364-B59EE490A766Q49884872-22A3AD95-377D-4F41-ABCE-4A70AF9952D8Q51062025-174A8E51-1079-4B20-847E-2EF4D82E2769Q54415087-1E85771B-F446-4078-ACA8-12CBD5BA655BQ55280710-D592F174-33E8-4A71-98FA-7576AD352201Q56888917-E63BAF32-44FC-444C-9930-583C1B44DA63
P2860
Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Kallikrein-related peptidase g ...... itoring of human malignancies.
@en
Kallikrein-related peptidase g ...... itoring of human malignancies.
@nl
type
label
Kallikrein-related peptidase g ...... itoring of human malignancies.
@en
Kallikrein-related peptidase g ...... itoring of human malignancies.
@nl
prefLabel
Kallikrein-related peptidase g ...... itoring of human malignancies.
@en
Kallikrein-related peptidase g ...... itoring of human malignancies.
@nl
P2860
P356
P1433
P1476
Kallikrein-related peptidase g ...... itoring of human malignancies.
@en
P2093
Margaritis Avgeris
P2860
P304
P356
10.1515/BC.2010.056
P577
2010-05-01T00:00:00Z